Anteris Technologies Reports Q3 2026 Results with $22.9M Net Operating Cash Outflows and PARADIGM Trial Expansion

Sonal Goyal

11 November 2026 12:32 PM AEDT

Anteris Technologies Reports Q3 2026 Results with $22.9M Net Operating Cash Outflows and PARADIGM Trial Expansion

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Anteris Technologies Global Corp. (ASX:AVR) has reported financial results for the quarter ended September 30, 2026, disclosing net operating cash outflows of $22.9 million and providing a corporate update covering PARADIGM Trial progress, a new facility occupancy, and a chief financial officer appointment.

Key Points

Net operating cash outflows for the three months ended September 30, 2026, were $22.9 million, primarily attributable to clinical, regulatory and manufacturing requirements supporting the PARADIGM Trial.
R&D expenses for the quarter were $21.3 million, driven by scaling of manufacturing and quality capabilities and PARADIGM Trial-related activities including patient enrollment costs.
The Company assumed occupancy as primary tenant of the Northcross facility in Brooklyn Park, Minnesota on September 1, providing additional production capacity for DurAVR THVs and the ComASUR Delivery System.
Brent Moen was appointed Chief Financial Officer, effective September 11, 2026.
Subsequent to quarter-end, the PARADIGM Trial received regulatory clearance from Germany's BfArM and received HREC approval and TGA authorisation under the Clinical Trial Notification pathway in Australia.

PARADIGM Trial Enrollment and Geographic Expansion

During the quarter ended September 30, 2026, Anteris continued execution of the global pivotal PARADIGM Trial across active sites in the United States, Canada and Europe, including Denmark, the Netherlands and France. The Company increased site activation in the United States and expanded the trial into Canada and France following completion of site qualification, investigator training and operational readiness activities. Subsequent to quarter-end, the trial received regulatory clearance from Germany's Federal Institute for Drugs and Medical Devices (BfArM), and in Australia received Human Research Ethics Committee approval and authorisation from the Therapeutic Goods Administration under the Clinical Trial Notification pathway.

Northcross Facility Occupancy and Production Capacity

On September 1, 2026, Anteris assumed occupancy as the primary tenant of the Northcross facility in Brooklyn Park, Minnesota. According to the filing, the facility provides additional capacity to scale production of the DurAVR THVs, the ComASUR Delivery System and related components in preparation for commercialisation. The ComASUR Delivery System is designed to support controlled deployment and accurate placement of the balloon-expandable DurAVR THV, which the company describes as a new class of biomimetic transcatheter aortic valve.

Q3 2026 Financial Results and R&D Expenditure

The Company's net operating cash outflows for the three months ended September 30, 2026, were $22.9 million, with the filing attributing this primarily to clinical, regulatory and manufacturing requirements supporting the ongoing PARADIGM Trial. R&D expenses of $21.3 million were driven by scaling of manufacturing and quality capabilities, including process development and validation activities and expanded headcount, together with PARADIGM Trial-related activities. The filing states these costs were partly offset by reduced DurAVR THV product research costs. Full financial details are contained in Anteris' Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.